Tag: Phase III Trial

Viaskin-Patch

FDA Removes Hold Allowing DBV’s Pivotal Phase 3 Peanut Patch Trial...

The phase 3 trial of the modified Viaskin Peanut patch has been cleared for commencement.
Xolair (omalizumab)

Biologic Showing Promise as Food Allergy Treatment in Ongoing Phase 3...

Assessment for both single agent and add-on therapy.
Palforzia Capsules with Logo

Positive Results from Phase 3 Study of PALFORZIA® in Peanut-Allergic Children...

73.5% of patients treated met the primary outcome at 12 months compared with 6.3% of patients in the placebo arm.
Viaskin Peanut

Private Law Firm to Investigate Claims on Behalf of Investors in...

It is unknown how this development will affect the ability of the company to eventually offer Viaskin Peanut as an FDA approved therapy.
Viaskin Peanut

FDA Issues Partial Hold on DBV Viaskin Peanut Patch Trial

Another delay for the long-awaited therapy.
eczema

Study Finds Biologic Drug Highly Effective in Reducing Pediatric Eczema Symptoms

Infants and young children finally get relief from eczema’s terrible itch
Viaskin Patch

DBV Begins Phase 3 Study of Redesigned Viaskin Peanut Patch in...

Viaskin is testing a new version of their patch designed to address the FDA's concerns.
Dupixent (dupilumab)

Dupixent® Phase 3 Trial Shows Positive Results in Children Ages 1-11...

Majority of patients achieved histological disease remission in 16 weeks.
Viaskin Patch

DBV Announces Positive Topline Results from Phase 3 Trial of Viaskin...

Viaskin Peanut demonstrated a statistically significant treatment effect with 67.0% of subjects meeting the treatment responder criteria after 12 months.
Atopic Dermatitis (Eczema)

Oral Medication Shows Strong Promise for Moderate to Severe Eczema in...

Upadacitinib yielded rapid and significant improvements in patients with moderate to severe atopic dermatitis in phase 3 trials.